UK-Norwegian team to develop living skin equivalent testing model

Published: 20-May-2013
Research & Development Skin Care Pharmaceutical

For testing inflammatory responses


Epistem, a UK-based biotechnology and personalised medicine company has joined forces with Norwegian firm ScandiDerma to develop a new in vitro human living skin equivalent model for testing inflammatory responses.

The collaboration is made possible through the UK's Technology Strategy Board and Innovation Norway following a successful application for funding in the ‘Sustainable high value chemical manufacture through industrial biotechnology’ competition.

The project starts this month and runs to March 2014 and will take place at project leader Epistem's facilities in Manchester, UK and ScandiDerma's facilities in Barents Biocenter, Tromsø, Norway.

  • Companies:
  • Epistem
  • Innovate UK
See more

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

Read more
In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  3. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Research & Development

Turntable-like catalytic reactor wins Innovate funding

The Spinning Disc Mesh Reactor developed by Bath chemical engineers aims to make pharmaceutical production safer and more sustainable
Media

Atelerix secures Innovate UK funding for cell transport tech

The funding will support the development of room temperature technologies for shipping therapeutic cells, as part of the company’s ‘BloodReady’ project
Ingredients

Research partnership removes bottleneck from AAV development

CPI, Cobra Biologics and GE Healthcare Life Sciences have developed a scalable, cost-effective purification process for adeno-associated viruses
Research & Development

UK government releases £125 million in grant funding to support innovators

The cash injection will see businesses turn ideas into new products and services on the market
Research & Development

Collaboration funds asthma diagnosis projects in the UK

Asthma UK and Innovate UK, have teamed up to fund three projects to help make diagnosis more accurate and treatment more efficient
Regulatory

Surge in cell and gene therapy trials highlight the UK’s leading position as developmental hub in this innovative industry

Global industry shows confidence in cell and gene therapies and in UK’s ability to deliver these life-changing products
Subscribe now